Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
FDA Files Corcept's New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
04:05pm, Monday, 03'rd Mar 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
01:25pm, Monday, 03'rd Mar 2025
NEW YORK , March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). Such investors
NEW YORK CITY, NY / ACCESS Newswire / March 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated ("Corcept" or "t
NEW YORK CITY, NY / ACCESS Newswire / March 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated ("Corcept" or "t
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
10:00am, Saturday, 01'st Mar 2025
NEW YORK CITY, NY / ACCESS Newswire / March 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ:CORT). Such
3 Reasons Why Growth Investors Shouldn't Overlook Corcept (CORT)
01:50pm, Friday, 28'th Feb 2025
Corcept (CORT) possesses solid growth attributes, which could help it handily outperform the market.
Why Corcept Therapeutics (CORT) is a Top Growth Stock for the Long-Term
10:50am, Friday, 28'th Feb 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Corcept Therapeutics (CORT) Outperforming Other Medical Stocks This Year?
10:40am, Friday, 28'th Feb 2025
Here is how Corcept Therapeutics (CORT) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.
NEW YORK CITY, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated ("Corcept" o
CORT's Q4 Earnings and Revenues Fall Short of Estimates
11:31am, Thursday, 27'th Feb 2025
Corcept reports weaker-than-expected results for the fourth quarter of 2024. Korlym drives year-over-year sales.
Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term
10:50am, Thursday, 27'th Feb 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
09:15am, Thursday, 27'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ:CORT)Such in
Corcept Therapeutics, Inc. (CORT) Q4 2024 Earnings Call Transcript
09:53pm, Wednesday, 26'th Feb 2025
Corcept Therapeutics, Inc. (NASDAQ:CORT ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants Atabak Mokari - CFO & Treasurer Gary Robb - Chief Business Officer & Secret
Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates
07:05pm, Wednesday, 26'th Feb 2025
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.28 per share a year ago.
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update
04:05pm, Wednesday, 26'th Feb 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
